Data of blastted subjects are available from the NCBI and Uniport Database; The raw sequence reads determined in this study have been deposited to DDBJ under the accession number DRA003058.

Introduction {#sec001}
============

Alveolar echinococcosis (AE) is a worldwide zoonosis that is of great public health concern in the northern hemisphere. Eggs of the tapeworm, which are excreted by definitive hosts, foxes and dogs, present a risk for humans \[[@pntd.0004634.ref001]\]. After oral ingestion of mature oncosphere-containing eggs, the oncospheres hatch in the small intestine of the intermediate host, and then migrate via the hepatic vein to the liver, where they form cyst masses and increasingly transform into multiple vesicles filled with fluid and protoscoleces \[[@pntd.0004634.ref002]\]. The metacestodes are lined with a germinal layer and a laminated layer, which allow the parasite to escape the host immune response and transition to the chronic stage in the liver \[[@pntd.0004634.ref003]--[@pntd.0004634.ref004]\].

It has been proven that infections can be blocked at the egg and early larval stages by antibodies and complement-dependent mechanisms \[[@pntd.0004634.ref005]\]. Furthermore, *in vitro* hatching and activation of oncosphere have been achieved, showing that oncosphere has an extended excretion apparatus and proteinases that may contribute to a considerable portion of the excreted proteins during the penetration process \[[@pntd.0004634.ref006], [@pntd.0004634.ref007], [@pntd.0004634.ref008], [@pntd.0004634.ref009]\]. The fact that the excretory/secretory proteins produced in the early (oncosphere) and chronic (metacestode) infectious stages by *E*. *multilocularis* can cause significant apoptosis or immature of the dendritic cells (DC) \[[@pntd.0004634.ref010]\] suggests that the early infective stage of *E*. *multilocularis* is a strong inducer of tolerance in DC, which is most probably important for producing an immunosuppressive environment in the infection phase.

Immune response to larval *Echoinococcus* spp. infections has been divided into "establishment" and "established metacestode" phases \[[@pntd.0004634.ref005], [@pntd.0004634.ref011]\]. And it is thought that the parasite are more susceptible to immune attack during early stages of infections ("establishment" phase) \[[@pntd.0004634.ref005], [@pntd.0004634.ref011]\]. The immunogenic to the tested models of numbers of recombinant proteins are available. It was reported that vaccine Eg95, which is based on the recombinant protein cloned from mRNA from the oncosphere of *E*. *granulosus* and shown to be highly effective in vaccine trials of sheep and had induced a high level of protection (96--100%) for more than a year post-vaccination \[[@pntd.0004634.ref012]\]. In addition, AgB \[[@pntd.0004634.ref013], [@pntd.0004634.ref014]\], EmY162 \[[@pntd.0004634.ref015]\], P29 \[[@pntd.0004634.ref016], [@pntd.0004634.ref017]\], EgEF \[[@pntd.0004634.ref018]\], Eg19 \[[@pntd.0004634.ref019]\] and TSPs \[[@pntd.0004634.ref002], [@pntd.0004634.ref020]\], derived from the *Echinococcus* spp., exhibit strong immunogenic properties in tested model, respectively. Furthermore, secondary AE, in which homogenates of the larval parasite are intraperitoneally, intravenously or intrahepatically injected into the host animals, is widely used; however, it does not reproduce the early stages of parasite development that occurs during natural infection via oral ingestion of the eggs \[[@pntd.0004634.ref021]\]. In addition, immunisation with *E*. *multilocularis* 14-3-3 protein protected intermediate hosts from primary but not secondary challenge infection with AE \[[@pntd.0004634.ref022]\]. One study show that the parasite lesions in the liver of primary AE at 4 weeks post inoculation varied among the strains of mice and suggests that the resistance to the early stages of parasite infections, including parasite establishment in the liver, is genetically regulated\[[@pntd.0004634.ref021]\].

Vaccination and early diagnosis are possible ways to control and prevent echinococcosis. Accurate immunodiagnosis of early infection requires highly specific and sensitive antigens. At present, little gene expression data has been published for egg and early larval stages. Thus, experiments on identifying antigens for use in immunodiagnostic assays is a crucial point in the improvement of the diagnostic tool and must be based on the developmental stage of the parasite.

The genome databases of *E*. *multilocularis* have recently become available \[[@pntd.0004634.ref023]\], and using the draft antigen families of *E*. *multilocularis*, gene expression profiles for adult and mature metecestode can be predicted, but transcriptomic profile datasets of the early larval stages (non-activated and activated oncospheres and immature metacestodes) are still unavailable.

As for mentioned above and gain understanding of the gene expression patterns for diagnostic assay and vaccine design, we analyzed the transcriptomes of non-activated and activated oncospheres, 4-week metacestodes miniature vesicles (Primary AE) and metacestodes small vesicles cultivated *in vitro* (Secondary AE) to identify homologues of the various known antigens of tapeworms, especially *Echinococcus* spp.

Materials and Methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

This study was carried out in strict accordance with the recommendations set out in the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Science, and the protocol for the animal experiments was approved by the ethics committee of the Hokkaido Institute of Public Health (permit number: K25-02).

Preparation of parasite samples {#sec004}
-------------------------------

*Echinococcus multilocularis* isolated in Hokkaido (Nemuro strain) was routinely maintained through a dog--cotton rat life cycle at the Hokkaido Institute of Public Health (Sapporo, Japan). Dogs were orally administered 5 × 10^5^ *E*. *multilocularis* protoscoleces and the infection was terminated 35--77 days postinfection by administering two tablets of Droncit\[[@pntd.0004634.ref024]\].

### Non-activated oncospheres (Nonc) {#sec005}

Feces were collected from experimentally infected dogs at 35 days postinfection. Eggs were isolated from feces by filtering by mesh, natural sedimentation and flotation with sugar solution. The isolated eggs were treated with 3% sodium hypochlorite for 20 mins for removal of the embryophore and sterilization. Non-activated oncospheres were collected at two times for biological replicates: September 2013 (sample, Nonc1) and December 2013 (sample, Nonc2).

### Activated oncospheres (Aonc) {#sec006}

Techniques for activation of non-activated oncospheres were as previously described \[[@pntd.0004634.ref006], [@pntd.0004634.ref009]\]. Briefly, non-activated oncospheres were activated with 1% pancreatin (Nacalai Tesque, Inc.), 1% hog bile extract (MP Biomedicals, LLC) and 0.2% Na~2~CO~3~ in RPMI 1640 (Gibco) at 38°C for 20 mins, and then cultivated in RPMI 1640 with 10% fetal calf serum (Gibco) at 38°C for 24 h.

### 4-week metacestodes miniature vesicles (4Wmet) {#sec007}

The DBA/2 mice were sacrificed after four weeks post oral infections with eggs and small lesions with early stage larvae were collected from the livers. The collected larvae were examined as 4-week metacestodes miniature vesicles (4Wmet).

### Metacestodes small vesicles cultivated *in vitro* (Cmet) {#sec008}

*In vitro* cultivation of *E*. *multilocularis* was carried out as described previously \[[@pntd.0004634.ref025], [@pntd.0004634.ref026]\]. In short, cyst masses of metacestodes from intraperitoneal passage DBA/2 mice at 16 weeks were cut into small pieces and cultivated in DMEM (Gibco) with 10% fetal calf serum (Gibco) at 37°C. Miniature cysts were grown to small vesicles (2--4 mm in diameter) in several weeks but were harvested before the formation of brood capsules and protoscoleces ([Fig 1](#pntd.0004634.g001){ref-type="fig"}).

![Morphology of different life cycle stages of *E*. *multilocularis*.\
A: Egg; B: Oncospheres (non-activated); C: Oncospheres (activating) with the hooks dispersive and body swelling; D: Oncospheres (activated) with the hooks aggregation in the smaller lobe after 24 hours activation; E: 4-week metacestodes miniature vesicles; F: Metacestodes small vesicles cultivated in vitro; Bar: 10μm (A-E), 1mm (F); Arrowhead: Miniature vesicles.](pntd.0004634.g001){#pntd.0004634.g001}

Construction of cDNA libraries {#sec009}
------------------------------

Total RNA was extracted from Nonc (2 samples), Aonc, 4Wmet and Cmet using Trizol Reagent (Life Technologies). The mRNA was extracted using the Illumina mRNA Seq Sample Preparation Kit according to manufacturer instructions. Briefly, total RNA was subjected to poly (A) selection using Sera-Mag Magnetic Oligo-dT beads. Poly (A+) RNA was partially degraded by incubating in fragmentation buffer at 94°C for 5 min. The first-strand cDNA was synthesized using random primers and SuperScript II (Invitrogen), and the second-strand cDNA was synthesized using RNaseH and DNA pol I (Illumina). Illumina GA sequencing adaptors were ligated to the cDNA ends. Double-stranded cDNA was size-fractionated by 6% polyacrylamide gel electrophoresis (PAGE), and the band of 200 bp cDNA was recovered and amplified using Phusion DNA Polymerase (Finnzymes) in 15 cycles by PCR. Finally, 100 bp pair end read RNA-seq tags were generated using the Genome Analyzer IIx (Illumina, San Diego, CA, USA) following methods in the User Guide.

RNA-Seq data analysis {#sec010}
---------------------

RNA-Seq reads obtained from non-activated oncospheres, activated oncospheres and metacestodes were filtered by perl script using the following criteria: 1) trim adapter; 2) remove Illumina-filtered reads; 3) remove reads with no-call bases (ex: AATC \"N\" ATGATAG); and 4) remove mouse-mapped reads. RNA-seq reads were mapped to *E*. *multilocularis* genome version 3 (<ftp://ftp.sanger.ac.uk/pub/project/pathogens/Echinococcus/multilocularis/genome/Emultilocularis_genome_v3.fas>) using Illumina Eland (Elandv2), and the mapped read number for each gene was first transformed into reads per kilobase per million reads (RPKM), then filtered tRNA and rRNA coding genes. In addition, to validate the Next-Generation Sequencing (NGS) data, eight genes common to the Nonc1 and Cmet were selected for real-time PCR analysis. The primers employed for amplification of the eight genes and glyceraldehyde 3-phosphate dehydrogenase (EmuJ_000254600, internal control) were designed by OligoArchitect (<http://www.oligoarchitect.com>) and are shown in [Table 1](#pntd.0004634.t001){ref-type="table"}. The real-time PCR was performed using Applied Biosystems 7300 Real-time PCR System with SYBR-Green detection (SYBR Premix, TaKaRa) according to the manufacturer's instructions. Each reaction was run in triplicate, after which the average threshold cycle (Ct) was calculated per sample and the relative expression of genes was calculated using the 2^-ΔΔCt^ method \[[@pntd.0004634.ref027]\]. Different expressed genes were then identified by the edgeR package \[[@pntd.0004634.ref028]\] with *p*\<0.01 and false discovery rate (FDR) smaller than 0.05.

10.1371/journal.pntd.0004634.t001

###### Primers for real-time PCR.

![](pntd.0004634.t001){#pntd.0004634.t001g}

  Genes            Forward primers         Reserve primers
  ---------------- ----------------------- ---------------------
  EmuJ_000212700   CGAAGGGTAATAAGGTGTA     TTGTAGAACTCACGATGT
  EmuJ_000342600   CTTCATCCACATTATCACT     CAGTAGTAGCCAAGGATA
  EmuJ_000355500   CGAAGGTGATGCTGAAGA      TCCGACCACAATGAAGAC
  EmuJ_000372400   CGAAGTGCTCAAGTCTGA      GCTAGAGTCGGCATTGTA
  EmuJ_000550000   AACTTCGTAGTCACTGAT      AGTCATCTCCTTGAACTT
  EmuJ_001077100   TTCTTCTTCAATGCCATT      TACCTCCAGACTTGTTAG
  EmuJ_001136900   TTCAATGCTACATCAGGTAAT   CGCCTACATTCCTTCTTAG
  EmuJ_000770300   AACATGAGTGAGGAGAAT      CGTAGAACTTGTAGACATC
  EmuJ_000254600   CTTCCAACTCTGTCAATG      GCTGTCAATAACCAACTT

Antigen homologues in *E*. *multilocularis* {#sec011}
-------------------------------------------

Putative antigen homologues of amino acid sequences in the *E*. *multilocularis* genome version 3 \[[@pntd.0004634.ref023]\] were identified using known antigen sequences (accession numbers shown below). Briefly, BLASTP \[[@pntd.0004634.ref029]\] comparisons were carried out using the amino acids sequences of *E*. *multilocularis* genome version 3 as queries and the known antigens sequences as subjects. Sequences with an E-value \< 1E^-25^ and identity value \> 80% were considered to be homologues of matched antigens within *Echinococcus* spp. Furthermore, antigen EG95 and diagnostic antigen gp50 family homologues were queried using the same amino acid sequences as used previously in the same genome version \[[@pntd.0004634.ref023]\].

Putative Em-TSP3 isoforms analysis {#sec012}
----------------------------------

Integrative Genomics Viewer \[[@pntd.0004634.ref030]\] was used to check the SNPs of the mapped reads at the putative Em-TSP3 isoform region of the scaffold. *De novo* assembled transcript sequences by the Trinity software \[[@pntd.0004634.ref031]\] for each sample were compared with Em-TSP3 isoforms identified by BLASTX \[[@pntd.0004634.ref015]\] using parameters--evalue 1e-20 -outfmt 6, and retained nucleotide sequences ([S1 Table](#pntd.0004634.s002){ref-type="supplementary-material"}) showed more than 90% identity to isoforms of putative Em-TSP3. The putative amino sequences of retained nucleotide sequences were predicted by OrfPredictor \[[@pntd.0004634.ref032]\], and aligned using Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>).

Accession numbers {#sec013}
-----------------

Accession numbers for various known *E*. *multilocularis*, *E*. *granulosus* and *Taenia solium* antigens sequences used in this study are as follows: *E*. *multilocularis* (CAA59739, CAA10109, AAL51153, BAC11863, BAC66949, BAC77657, BAD89809, BAD89810, BAD89811, BAD89812, Q8WT41, BAF02516, BAF02517, BAF63674, BAF79609, ACJ02401, ACJ02402, ACJ02403, ACJ02404, ACJ02405, ACJ02406, ACJ02407, BAJ83490, BAJ83491, AER10547, AHA85399, Q07840, Q24895, Q24902, Q27652, Q8MM75, Q8WPI6, Q8WT42, Q9GP32, Q9NFZ5, Q9NFZ6, and Q9NFZ7); *E*. *granulosus* (AAF02297, AAL87239, CAF18421, AAX20156, AAX73175, ACA14465, ACA14466, ACA14467, ABI24154, AFI71096, AGE12481, AGE12482, O16127, O17486, O46119, P14088, P35417, P35432, Q02970, Q03341, Q03342, Q04820, Q07839, Q24789, Q24798, Q24799, Q24800, Q8MUA4, Q8T6C4, Q95PU1, Q9BMK3, Q9GP33, Q9GP38, Q9U408 and Q9U8G7); and *T*. *solium* (AAP49286, AAP49287, AAP49288, AAP49284 and AAP49285).

The raw sequence reads determined in this study have been deposited to DDBJ under the accession number DRA003058.

Results and Discussion {#sec014}
======================

RNA-Seq data analysis {#sec015}
---------------------

We constructed five cDNA libraries from Nonc1, Nonc2, Aonc, 4Wmet and Cmet of *E*. *multilocularis* ([Fig 1](#pntd.0004634.g001){ref-type="fig"}). More than 493 million clean reads were generated by Illumina paired-end sequencing, and 9,852 coding sequences of the genome were mapped with RPKM bigger than zero in at least one of the sequenced samples ([S2 Table](#pntd.0004634.s003){ref-type="supplementary-material"}). The quality of obtained reads was excellent with more than 90% of reads having a quality score at Q30 (error probability of 0.001) or higher ([Table 2](#pntd.0004634.t002){ref-type="table"}). The results of real-time PCR analysis confirmed the NGS analysis data and show similar trends in fold change ([Fig 2](#pntd.0004634.g002){ref-type="fig"}).

10.1371/journal.pntd.0004634.t002

###### Overview of the sequencing reads.

![](pntd.0004634.t002){#pntd.0004634.t002g}

  Samples   Yield (Mbases)   \% PF[\*](#t002fn001){ref-type="table-fn"}   Raw Reads     Clean Reads(mouse mapped reads filtered)   \% of \> = Q30 Bases (%PF)[^\#^](#t002fn002){ref-type="table-fn"}   Mean Quality Score (%PF)
  --------- ---------------- -------------------------------------------- ------------- ------------------------------------------ ------------------------------------------------------------------- --------------------------
  Nonc1     13,251           93.34                                        141,966,744   131,761,968                                91.66                                                               35.74
  Nonc2     13,870           94.45                                        146,847,812   136,531,516                                93.53                                                               36.39
  Aonc      12,735           94.76                                        134,400,788   126,184,658                                93.48                                                               36.24
  4Wmet     12,430           93.77                                        132,558,666   231,874                                    91.36                                                               35.79
  Cmet      10,051           93.57                                        107,407,454   98,702,084                                 90.28                                                               35.38

**\***%PF: The total fraction of passing filter reads assigned to an index.

^**\#**^Q30:1 in 1000 base is mistake.

Nonc1: Non-activated oncosphere 1; Nonc2: Non-activated oncosphere2; Aonc: Activated oncosphere; 4Wmet: 4-week metacestodes miniature vesicles; Cmet: Metacestodes small vesicles cultivated *in vitro*.

![Real-time PCR validation of genes at kinds of expression level.\
The y-axis indicates the value of relative expression level (2^-ΔΔCt^) by real-time PCR and log~2~Ratio of Nonc1/Cmet by Next-generation sequencing. GAPDH as the internal control. Error Bar: Standard Deviation of the mean expression values of Real-time PCR.](pntd.0004634.g002){#pntd.0004634.g002}

Larval tissue in the liver of 1--3 weeks post oral infections in DBA/2 mice were very small. After four weeks post oral infections, the lesions were identified in the livers and lesions with the parasite (4Wmet) were separated and extracted. The extracted sample contain more host tissue than the parasites which cause the number of reads were significantly decreased by filtering the mouse-mapped reads of 4Wmet ([Table 2](#pntd.0004634.t002){ref-type="table"}). But the cluster results showed a closer relationship with Cmet ([Fig 3](#pntd.0004634.g003){ref-type="fig"}), which is in accordance with the biological development of *E*. *multilocularis*. For differentially expressed gene (DEG) analysis, we divided the cDNA libraries into biological development stages of non-activated oncosphere (Nonc1 and Nonc2), activated oncosphere (Aonc) and early stage metacestode (4Wmet, Cmet). There were 187 DEGs in the activated oncosphere versus non-activated oncosphere, 443 in activated oncosphere versus early stage metacestode and 1,433 in non-activated oncosphere versus early stage metacestode ([Fig 4](#pntd.0004634.g004){ref-type="fig"} and [S2 Table](#pntd.0004634.s003){ref-type="supplementary-material"}). In total, there were 1,491 DEGs, and most of the genes identified between non-activated oncosphere versus early stage metacestode were also identified between activated oncosphere versus early stage metacestode ([S2 Table](#pntd.0004634.s003){ref-type="supplementary-material"}). Almost DEGs were up-regulated when non-activated oncospheres transformed to activated oncospheres ([Fig 4](#pntd.0004634.g004){ref-type="fig"}).

![Heatmap showing the Euclidean distances between the samples as calculated from the variance stabilizing transformation of the count data by DEGseq pakage \[[@pntd.0004634.ref033]\].\
Nonc1: Non-activated oncosphere 1; Nonc2: Non-activated oncosphere2; Aonc: Activated oncosphere; 4Wmet: 4-week metacestodes miniature vesicles; Cmet: Metacestodes small vesicles cultivated *in vitro*.](pntd.0004634.g003){#pntd.0004634.g003}

![Analyses of differentially expressed genes (DEGs) among non-activated oncophere (Nonc), activated oncosphere (Aonc) and early stage of metacestode (Emet).](pntd.0004634.g004){#pntd.0004634.g004}

Diagnostic antigen gp50 subunits in activated oncospheres {#sec016}
---------------------------------------------------------

In this transcriptome datasets, 27 isoforms coding diagnostic antigen gp50 (GP50) mapped to 34 isoforms of the genome ([S3 Table](#pntd.0004634.s004){ref-type="supplementary-material"}). Of the genome isoforms of GP50, 97.06% (33/34) were not expressed (RPKM\<1) in Cmet, while 29.41% (10/34) were expressed (RPKM\>1) in 4Wmet. Six GP50 isoforms were highly expressed (RPKM\>100) in Aonc ([Table 3](#pntd.0004634.t003){ref-type="table"}), and five isoforms showed significantly higher expression (*p*\<0.01, PDR\<0.05) in the stage of activated oncospheres compared with non-activated oncospheres or the early stage metacestodes ([Table 3](#pntd.0004634.t003){ref-type="table"}). All six of the highly expressed GP50 had potential signal peptides, but only one had a GPI anchor ([S3 Table](#pntd.0004634.s004){ref-type="supplementary-material"}).

10.1371/journal.pntd.0004634.t003

###### The antigen homologues matched to *E*. *multilocularis* proteome.
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  Gene ID          Accession number   Description                                  Species                 Identity   E-value     Nonc1      Nonc2       Aonc       4Wmet       Cmet        Nonc vs Aonc   Nonc vs Emet   Aonc vs Emet
  ---------------- ------------------ -------------------------------------------- ----------------------- ---------- ----------- ---------- ----------- ---------- ----------- ----------- -------------- -------------- --------------
  EmuJ_000364000   Q8MM75             14-3-3 protein homolog 2                     *E*. *multilocularis*   99.58      8.00E-178   2,497.64   3,110.31    1,570.28   1,555.32    3,675.01    0.951          0.694          0.784
  EmuJ_001192500   AAX73175           14-3-3 protein zeta                          *E*. *granulosus*       98.39      0           1,737.74   2,488.74    2,087.08   2,202.17    1,785.08    1.000          0.635          0.979
  EmuJ_000407200   P35432             ACTI                                         *E*. *granulosus*       97.87      0           0.28       0.22        16.30      9.20        250.48      0.006          0.000          0.258
  EmuJ_000406900   P35432             ACTI                                         *E*. *granulosus*       97.07      0           0.26       0.42        30.92      4.60        433.97      0.023          0.000          0.458
  EmuJ_000407300   Q03341             ACTII                                        *E*. *granulosus*       99.73      0           0.00       0.00        0.30       13.77       6.32        0.026          0.000          0.049
  EmuJ_000006900   Q03341             ACTII                                        *E*. *granulosus*       88.1       2.00E-24    0.00       0.00        0.00       0.00        2.33        NA             NA             NA
  EmuJ_000036300   Q03342             ACTIII                                       *E*. *granulosus*       98.38      0           2,990.42   895.40      1,196.83   668.68      785.70      1.000          0.166          0.932
  EmuJ_000190400   Q03342             ACTIII                                       *E*. *granulosus*       98.38      0           2,877.54   1,631.00    1,204.67   799.28      709.87      0.921          0.071          0.939
  EmuJ_000701700   Q03342             ACTIII                                       *E*. *granulosus*       94.57      0           0.04       0.03        0.15       941.02      78.61       1.000          0.000          0.000
  EmuJ_000061200   Q03342             ACTIII                                       *E*. *granulosus*       94.5       0           0.76       0.63        1.64       3,007.91    219.08      1.000          0.000          0.000
  EmuJ_000703300   Q03342             ACTIII                                       *E*. *granulosus*       94.5       0           0.01       0.00        0.21       653.62      21.65       0.285          0.000          0.001
  EmuJ_000184900   AFI71096           Antigen 5                                    *E*. *granulosus*       96.69      0           71.79      22.04       18.02      157.05      750.33      0.922          0.008          0.017
  EmuJ_001090800   Q07840             Antigen EM13                                 *E*. *multilocularis*   100        1E-54       711.79     77.84       569.71     87.38       99.98       1.000          0.095          0.183
  EmuJ_000601200   AGE12481           Calcineurin A                                *E*. *granulosus*       96.83      0           69.94      11.42       39.08      47.93       32.96       1.000          0.974          0.959
  EmuJ_000447500   AGE12482           Calcineurin B                                *E*. *granulosus*       98.79      3E-118      111.71     76.24       128.98     49.11       68.06       1.000          0.352          0.776
  EmuJ_000454300   AER10547           Calcineurin B                                *E*. *multilocularis*   100        4E-122      173.21     121.50      89.68      95.03       63.01       0.896          0.202          0.992
  EmuJ_000920600   P14088             CYP-1                                        *E*. *granulosus*       99.38      5E-117      2,667.92   3,688.78    4,128.27   3,793.82    5,244.75    1.000          0.975          0.948
  EmuJ_000517100   AAF02297           EF-1                                         *E*. *granulosus*       96.72      1E-177      1,247.18   1,550.50    1,026.26   664.44      516.83      1.000          0.119          0.907
  EmuJ_000982200   BAF63674           EF1a                                         *E*. *multilocularis*   100        0           5,448.38   4,948.33    4,644.50   4,335.45    4,854.90    1.000          0.646          0.970
  EmuJ_000342900   ABI24154           EG19                                         *E*. *granulosus*       84.93      2E-71       1.35       1.13        4.23       3.39        31.82       1.000          0.022          0.498
  EmuJ_000485800   CAA10109           Elp (Antigen II/3)                           *E*. *multilocularis*   100        0           3,971.70   3,429.81    3,767.91   1,741.57    692.90      1.000          0.063          0.567
  EmuJ_000368620   AAL51153           EM95[\*](#t003fn001){ref-type="table-fn"}    *E*. *multilocularis*   95.68      6E-111      17.36      39.73       6,843.39   237.19      0.10        0.055          0.690          0.078
  EmuJ_000368610   AAL51153           EM95[\*](#t003fn001){ref-type="table-fn"}    *E*. *multilocularis*   54.42      2.00E-41    0.00       0.00        0.00       0.00        0.00        NA             NA             NA
  EmuJ_000375200   AAL51153           EM95[\*](#t003fn001){ref-type="table-fn"}    *E*. *multilocularis*   31         4.00E-16    82.67      98.24       43.72      0.00        0.14        0.805          0.000          0.000
  EmuJ_000328500   Q8WPI6             ONCO1[\*](#t003fn001){ref-type="table-fn"}   *E*. *multilocularis*   99.36      7E-114      8,103.46   11,240.87   7,689.15   419.02      3.09        1.000          0.002          0.042
  EmuJ_000710400   Q8WPI6             ONCO1[\*](#t003fn001){ref-type="table-fn"}   *E*. *multilocularis*   41.67      4.00E-25    4,060.23   8,327.44    5,174.72   91.30       1.51        1.000          0.000          0.003
  EmuJ_000381200   BAC77657           EmAgB8/1                                     *E*. *multilocularis*   100        1E-57       1.08       0.00        1.43       4,616.70    9,199.96    1.000          0.000          0.000
  EmuJ_000381100   BAD89809           EmAgB8/2                                     *E*. *multilocularis*   100        8E-63       1.17       0.00        0.25       329.74      3,576.08    1.000          0.000          0.000
  EmuJ_000381600   BAD89811           EmAgB8/3                                     *E*. *multilocularis*   100        1E-58       0.80       8.54        24.25      656.66      961.72      1.000          0.000          0.040
  EmuJ_000381700   BAD89811           EmAgB8/3                                     *E*. *multilocularis*   100        1E-58       0.68       8.54        4.44       490.84      496.97      1.000          0.000          0.010
  EmuJ_000381500   BAD89811           EmAgB8/3                                     *E*. *multilocularis*   92.05      6E-52       3.93       0.56        164.90     10,971.19   21,686.21   0.000          0.000          0.001
  EmuJ_000381400   BAD89810           EmAgB8/4                                     *E*. *multilocularis*   100        2E-60       1.74       0.00        1.92       2,590.48    7,539.59    1.000          0.000          0.000
  EmuJ_000381800   BAD89812           EmAgB8/5                                     *E*. *multilocularis*   100        4E-57       0.00       0.00        0.03       0.00        0.07        NA             NA             NA
  EmuJ_000790200   BAJ83490           EmCBP1                                       *E*. *multilocularis*   100        0           2.48       1.42        114.41     232.80      445.61      0.000          0.000          0.387
  EmuJ_000790300   BAJ83491           EmCBP2                                       *E*. *multilocularis*   100        0           7.57       2.49        40.14      20.42       19.16       0.201          0.137          0.855
  EmuJ_000654500   BAF02516           EmCLP1                                       *E*. *multilocularis*   100        0           0.01       0.00        0.36       0.00        0.04        NA             NA             NA
  EmuJ_000654600   BAF02516           EmCLP1                                       *E*. *multilocularis*   100        0           0.00       0.00        0.00       0.00        0.00        NA             NA             NA
  EmuJ_000654100   BAF02516           EmCLP1                                       *E*. *multilocularis*   97.93      0           0.11       0.00        0.29       0.00        0.14        NA             NA             NA
  EmuJ_000654200   BAF02516           EmCLP1                                       *E*. *multilocularis*   94.67      0           0.00       0.00        0.00       0.00        0.00        NA             NA             NA
  EmuJ_000654800   BAF02516           EmCLP1                                       *E*. *multilocularis*   94.67      0           0.00       0.00        0.00       0.00        0.00        NA             NA             NA
  EmuJ_000989200   BAF02517           EmCLP2                                       *E*. *multilocularis*   100        0           69.37      48.92       80.50      59.57       54.45       1.000          0.715          0.971
  EmuJ_000941000   BAC66949           EmDLC                                        *E*. *multilocularis*   100        9E-56       3.77       3.10        98.82      163.54      721.24      0.004          0.000          0.252
  EmuJ_000940900   BAC66949           EmDLC                                        *E*. *multilocularis*   88.31      7E-52       33.87      24.80       252.73     2,531.92    3,470.81    0.209          0.000          0.025
  EmuJ_000590100   BAC66949           EmDLC                                        *E*. *multilocularis*   83.12      4E-46       36.66      34.27       64.78      100.36      123.22      1.000          0.354          0.749
  EmuJ_000941100   BAC66949           EmDLC                                        *E*. *multilocularis*   83.12      1E-49       5.12       6.98        64.69      124.08      946.12      0.379          0.000          0.147
  EmuJ_000946700   BAC66949           EmDLC                                        *E*. *multilocularis*   83.12      2E-48       324.29     647.14      812.70     25.62       7.96        1.000          0.000          0.000
  EmuJ_001060400   BAC66949           EmDLC                                        *E*. *multilocularis*   83.12      8E-46       127.77     180.55      268.92     474.48      763.07      1.000          0.212          0.561
  EmuJ_000940800   BAC66949           EmDLC                                        *E*. *multilocularis*   81.82      1E-48       0.96       0.57        15.94      37.20       120.86      0.061          0.000          0.331
  EmuJ_000538300   CAA59739           EMGST1                                       *E*. *multilocularis*   100        1E-165      553.09     531.84      697.37     1,395.50    1,515.60    1.000          0.474          0.642
  EmuJ_000791700   BAC11863           EmTRX                                        *E*. *multilocularis*   100        2E-146      1,182.52   1,611.54    2,307.76   2,834.87    2,684.39    1.000          0.808          0.920
  EmuJ_000515900   BAF79609           EMY162                                       *E*. *multilocularis*   98.04      1E-109      0.08       0.10        3.98       0.00        19.00       0.133          0.002          0.775
  EmuJ_000021700   BAF79609           EMY162                                       *E*. *multilocularis*   89.32      1E-67       0.00       0.00        0.03       0.00        0.00        NA             NA             NA
  EmuJ_000564900   BAF79609           EMY162                                       *E*. *multilocularis*   84.67      4E-92       48.88      162.47      639.91     73.97       146.34      0.935          0.677          0.258
  EmuJ_000492700   AAL87239           EpC1                                         *E*. *granulosus*       94.37      4E-43       10.88      7.44        75.29      954.51      1,717.34    0.256          0.000          0.012
  EmuJ_000550000   Q02970             FABP1                                        *E*. *granulosus*       93.23      9E-90       1.61       2.16        61.61      361.74      593.83      0.001          0.000          0.052
  EmuJ_000549800   Q9BMK3             FABP2                                        *E*. *granulosus*       99.25      1E-95       0.14       0.37        1.66       167.93      199.22      0.899          0.000          0.000
  EmuJ_000905600   Q9GP32             FBPA                                         *E*. *multilocularis*   99.72      0           946.48     570.08      349.68     1,013.07    3,354.39    0.921          0.363          0.161
  EmuJ_000382200   O46119             Ferritin                                     *E*. *granulosus*       96.53      2E-125      5,317.20   7,184.38    4,466.66   5,359.65    14,599.80   1.000          0.944          0.669
  EmuJ_000254600   Q27652             GAPDH                                        *E*. *multilocularis*   96.9       0           7,190.54   952.35      2,507.29   3,511.48    9,918.31    1.000          0.618          0.585
  EmuJ_000515500   AAP49287           GP50b[\*](#t003fn001){ref-type="table-fn"}   *T*. *solium*           40.75      1.00E-67    442.74     503.43      174.93     4.24        0.12        0.770          0.000          0.000
  EmuJ_000261100   AAP49287           GP50b[\*](#t003fn001){ref-type="table-fn"}   *T*. *solium*           40.87      5.00E-65    0.06       0.58        1,203.70   56.40       0.21        0.001          0.030          0.087
  EmuJ_000049700   AAP49287           GP50b[\*](#t003fn001){ref-type="table-fn"}   *T*. *solium*           34.47      5.00E-43    32.51      13.58       542.58     184.22      0.01        0.543          0.584          0.633
  EmuJ_000512300   AAP49287           GP50b[\*](#t003fn001){ref-type="table-fn"}   *T*. *solium*           33.05      7.00E-43    0.00       0.11        499.58     14.91       0.00        0.000          0.024          0.029
  EmuJ_000293700   AAP49288           GP50c[\*](#t003fn001){ref-type="table-fn"}   *T*. *solium*           37.58      9.00E-68    431.40     537.43      420.06     5.96        0.02        1.000          0.000          0.000
  EmuJ_000681200   AAP49288           GP50c[\*](#t003fn001){ref-type="table-fn"}   *T*. *solium*           33.22      2.00E-43    8.85       4.21        279.76     334.10      6.83        0.019          0.006          0.928
  EmuJ_000249600   Q24895             GRP78(HSP70)                                 *E*. *multilocularis*   99.85      0           185.09     159.39      372.98     266.34      222.14      1.000          0.987          0.953
  EmuJ_000212700   Q8WT42             HSP20(Onco2)                                 *E*. *multilocularis*   100        0           6,878.11   6,212.35    1,352.09   388.39      100.30      0.330          0.000          0.205
  EmuJ_001085100   Q24789             HSP70                                        *E*. *granulosus*       96.54      0           225.68     28.47       838.10     377.73      359.20      0.271          0.212          0.783
  EmuJ_000723700   Q24789             HSP70                                        *E*. *granulosus*       91.73      5E-152      7.80       0.82        13.62      6.81        14.43       1.000          0.396          1.000
  EmuJ_001085400   Q24789             HSP70                                        *E*. *granulosus*       90.73      0           3,095.23   1,216.16    2,699.23   1,063.90    1,557.45    1.000          0.472          0.838
  EmuJ_000417100   Q04820             MDH                                          *E*. *granulosus*       97.89      0           192.94     195.02      514.29     925.42      2,753.59    1.000          0.018          0.396
  EmuJ_001185000   CAF18421           Mdhm                                         *E*. *granulosus*       99.11      0           28.21      26.27       96.18      95.32       105.92      1.000          0.171          0.945
  EmuJ_001185100   CAF18421           Mdhm                                         *E*. *granulosus*       99.04      0           35.39      48.46       275.68     194.92      190.08      0.614          0.171          0.971
  EmuJ_000653900   Q24799             Myophilin                                    *E*. *granulosus*       98.82      5E-125      5.44       12.99       4.49       18.76       316.68      1.000          0.020          0.048
  EmuJ_000550800   AHA85399           P29                                          *E*. *multilocularis*   99.58      6E-177      326.60     307.02      375.86     314.76      521.18      1.000          0.978          0.932
  EmuJ_000763300   P35417             Paramyosin                                   *E*. *granulosus*       98.96      0           0.21       0.16        0.25       19.36       200.49      1.000          0.000          0.000
  EmuJ_001193100   Q8WT41             Serpin^Emu^                                  *E*. *multilocularis*   100        0           197.45     206.12      27.81      19.50       9.69        0.068          0.000          0.860
  EmuJ_001193200   Q8WT41             Serpin^Emu^                                  *E*. *multilocularis*   99.72      0           158.01     165.38      23.16      6.49        1.66        0.066          0.000          0.160
  EmuJ_000372400   AAX20156           Tegumental protein                           *E*. *granulosus*       84.31      4E-25       8.96       11.48       9,293.21   20,701.84   7,556.48    0.000          0.000          0.861
  EmuJ_000602100   O17486             Thioredoxin                                  *E*. *granulosus*       98.13      7E-67       89.06      101.37      140.04     99.31       118.35      1.000          0.834          0.993
  EmuJ_000958100   Q95PU1             Tropomyosin                                  *E*. *granulosus*       100        0           147.90     59.78       142.03     89.08       63.22       1.000          0.532          0.844
  EmuJ_000355800   ACJ02402           Em-TSP1                                      *E*. *multilocularis*   100        0           0.12       0.16        8.06       139.89      111.06      0.000          0.000          0.010
  EmuJ_001070300   ACJ02403           Em-TSP2                                      *E*. *multilocularis*   100        2E-148      24.46      23.81       69.16      175.63      176.58      1.000          0.012          0.429
  EmuJ_000328400   ACJ02404           Em-TSP3                                      *E*. *multilocularis*   100        6E-107      19.95      0.08        6.47       0.00        0.45        1.000          0.062          0.278
  EmuJ_001077400   ACJ02404           Em-TSP3                                      *E*. *multilocularis*   100        6E-107      229.08     0.07        76.69      40.67       1.38        1.000          0.412          0.777
  EmuJ_000289200   ACJ02404           Em-TSP3                                      *E*. *multilocularis*   91.22      5E-97       0.00       0.00        0.00       0.00        0.00        NA             NA             NA
  EmuJ_001077200   ACJ02404           Em-TSP3                                      *E*. *multilocularis*   91.22      5E-97       0.00       0.00        0.00       0.00        0.00        NA             NA             NA
  EmuJ_001077300   ACJ02404           Em-TSP3                                      *E*. *multilocularis*   91.22      5E-97       229.06     0.07        76.69      40.67       1.13        1.000          0.416          0.777
  EmuJ_001021500   ACJ02405           Em-TSP4                                      *E*. *multilocularis*   100        9E-167      14.97      18.48       73.14      415.80      152.32      0.952          0.001          0.277
  EmuJ_001077100   ACJ02406           Em-TSP5                                      *E*. *multilocularis*   100        1E-161      15.32      14.63       668.99     1,062.25    2,961.54    0.001          0.000          0.471
  EmuJ_001021300   ACJ02407           Em-TSP6                                      *E*. *multilocularis*   99.55      1E-161      62.14      83.07       78.16      353.52      310.79      1.000          0.152          0.219
  EmuJ_000834300   ACJ02401           Em-TSP7                                      *E*. *multilocularis*   100        2E-168      59.30      38.08       86.46      72.75       127.43      1.000          0.559          0.893
  EmuJ_000202600   Q9NFZ7             TUB-1                                        *E*. *multilocularis*   100        0           0.80       1.31        13.77      364.22      578.46      0.158          0.000          0.006
  EmuJ_000672200   Q9NFZ6             TUB-2                                        *E*. *multilocularis*   100        0           745.95     531.67      1,037.80   1,444.02    2,979.22    1.000          0.249          0.637
  EmuJ_000069900   Q9NFZ6             TUB-2                                        *E*. *multilocularis*   96.51      0           0.63       0.08        0.53       102.21      0.26        NA             NA             NA
  EmuJ_000569000   Q9NFZ6             TUB-2                                        *E*. *multilocularis*   96.28      0           0.19       0.05        1.46       5.18        1.90        0.286          0.004          0.784
  EmuJ_000955100   Q9NFZ6             TUB-2                                        *E*. *multilocularis*   96.05      0           0.48       0.39        1.01       2.59        0.51        1.000          0.681          0.975
  EmuJ_000617000   Q9NFZ6             TUB-2                                        *E*. *multilocularis*   94.19      0           0.02       0.00        0.04       406.27      0.23        NA             NA             NA
  EmuJ_000041100   Q9NFZ6             TUB-2                                        *E*. *multilocularis*   80.14      0           1.91       0.62        5.07       6.47        1.09        1.000          0.578          0.965
  EmuJ_000202500   Q9NFZ5             TUB-3                                        *E*. *multilocularis*   100        0           23.71      12.67       296.90     647.27      1,307.92    0.017          0.000          0.355

\*Identified by previous study \[[@pntd.0004634.ref023]\]

Nonc: Non-actvated oncospheres; Aonc: Activated oncospheres; Emet: Early stage metacestodes.

NA: Genes were filtered when executed significant gene expression.

*Taenia solium* GP50 has been used for the diagnosis of cysticercosis \[[@pntd.0004634.ref034]\]. GP50 isoforms are species-specific antigens and may be stage-specific in *Cysticercus cellulosae* \[[@pntd.0004634.ref035]\] based on the lack of antibody reactivity with one serum sample from an individual confirmed to be taeniasis-positive but cysticercosis-negative \[[@pntd.0004634.ref035]\]. A previous study showed that more than 90% of *E*. *multilocularis* GP50 isoforms were not expressed in metacestodes cultivated *in vitro* \[[@pntd.0004634.ref023]\], and our present work also corroborated this finding, as few or no transcripts of GP50 were found in Cmet. Some GP50 isoforms were expressed in 4Wmet from *in vivo* DBA/2 mice infections, suggesting that these GP50 isoforms are key factors in the host-parasite interface during the early stage of infection. GP50 antigen family expression also showed quite high variability ([Fig 5](#pntd.0004634.g005){ref-type="fig"}), and the lack of uniformity of isoform expression in oncospheres (non-activated and activated) and adults (pre-gravid and gravid) ([Fig 5](#pntd.0004634.g005){ref-type="fig"}) indicates that the *E*. *multilocularis* diagnostic antigen GP50 may be stage-specific as well.

![Phylogenetic analyses of diagnostic antigen gp50 amino acid sequences.\
The neighbor-joining tree was constructed by MEGA 6.0 ([www.megasoftware.net](http://www.megasoftware.net)); bootstrap values were obtained from 1,000 replicates. Nonc: RPKM\>100 at stages of non-activated oncosphere; Aonc: RPKM\>100 at stages of activated oncosphere; P_gravid: FPKM\>100 at stage of pre-gravid \[[@pntd.0004634.ref023]\]; Gravid: FPKM\>100 at stage of gravid \[[@pntd.0004634.ref023]\].](pntd.0004634.g005){#pntd.0004634.g005}

EG95 (Fibronectin type III-like) in activated and non-activated oncospheres {#sec017}
---------------------------------------------------------------------------

Previous studies have described the effectiveness of Fibronectin type III domain-like protein vaccines against echinococcosis \[[@pntd.0004634.ref015], [@pntd.0004634.ref036], [@pntd.0004634.ref037]\]. These highly immunogenic proteins, which may be involved in host invasion, are encoded by a multigene family; EG95 vaccine is effective against *E*. *granulosus*, and EM95 is effective against *E*. *multilocularis* \[[@pntd.0004634.ref036], [@pntd.0004634.ref038]\]. The antigen is a secreted protein with a GPI anchor that is upregulated during oncosphere activation \[[@pntd.0004634.ref038], [@pntd.0004634.ref039]\] and is probably involved in cell adhesion \[[@pntd.0004634.ref040]\]. Three (EmuJ_000328500, EmuJ_000368620, EmuJ_000710400) out of five EG95 relatives followed the previous prediction \[[@pntd.0004634.ref023]\], and corresponded to the top 20 expressed proteins in non-activated and activated oncospheres ([S2 Table](#pntd.0004634.s003){ref-type="supplementary-material"}). Unlike EmuJ_000328500 and EmuJ_000368620, the highly expressed EmuJ_000710400 showed low identity with the published EM95 antigens ([Table 3](#pntd.0004634.t003){ref-type="table"}), suggesting that it may be a new candidate antigen for vaccine development against alveolar echinococcosis. Most interestingly, EmuJ_000368620 which shows highest identity to EM95 is significantly expressed in activated oncospheres ([Table 3](#pntd.0004634.t003){ref-type="table"}). However, EmuJ_000328500 which shows highest identity to ONCO1 (79.5% identity to EM95) is highest expression in non-activated oncospheres ([Table 3](#pntd.0004634.t003){ref-type="table"}). It is not surprised that EmuJ_000328500 has the highest expression level in the non-activated oncospheres in accordance with the data from previous study \[[@pntd.0004634.ref041]\].

EMY162, a potential vaccine candidate against *E*. *multilocularis*, showed 31.4% identity to the amino acid sequence of EM95, which is also a fibronectin type III-containing protein \[[@pntd.0004634.ref015]\].

EmuJ_000564900 (85% identity to BAF79609) was expressed in most of the life-cycles stages, especially in activated oncospheres ([Table 3](#pntd.0004634.t003){ref-type="table"}), EmuJ_000021700 (89% identity to the BAF79609) showed almost no expression in sequenced samples of our present work ([Table 3](#pntd.0004634.t003){ref-type="table"}), and EmuJ_000515900 (98% identity to the BAF79609) primarily expressed in cultured small vesicles in our study ([Table 3](#pntd.0004634.t003){ref-type="table"}), which is consistent with findings in a previous study \[[@pntd.0004634.ref015], [@pntd.0004634.ref023]\].

Serine protease inhibitors predominated in non-activated oncosphere {#sec018}
-------------------------------------------------------------------

Serpins (serine proteinase inhibitors) constitute a huge family of about 1,500 identified members. The function of serpins ranges from the regulation of proteinases from immune effector cells, blood coagulation and in the complement system in mammals \[[@pntd.0004634.ref042]\]. The serpin of *E*. *multilocularis* (serpin^Emu^) was the first member described from this class of cestodes \[[@pntd.0004634.ref041]\], and sequence analysis indicated that it was an intracellular serpin \[[@pntd.0004634.ref041], [@pntd.0004634.ref043]\]. The putative amino acid sequences of the parasite genome data \[[@pntd.0004634.ref023]\] suggested that serpin^Emu^ with a signal peptide predicted by Phobius \[[@pntd.0004634.ref044]\]. In addition, *in vitro* assays have confirmed that serpin^Emu^ fails to inhibit cathepsin G and chymotrypsin but can readily inhibit trypsin and pancreatic elastase \[[@pntd.0004634.ref043]\], both of which are digestive enzymes in the intestines of mammals. Therefore, an extracellular role of serpin^Emu^ may be possible. Previous descriptions of the ultrastructure of *E*. *granulosus* oncospheres have referred to the penetration gland cells \[[@pntd.0004634.ref045]\] and proteinases may make up a considerable portion of the excreted proteins during the penetration process that is hypothesized to involve the secretion that may help the parasite penetrate the intestinal wall of the intermediate host \[[@pntd.0004634.ref006], [@pntd.0004634.ref007],[@pntd.0004634.ref045], [@pntd.0004634.ref046]\]. If serpin^Emu^ is excreted by penetration gland during the infection phase of the oncospheres, it might be able to block the proteolytic attack of host digestive enzymes. If so, it may even be a target of the intestinal immune system and a vaccine candidate.

HSPs antigens constantly expressed in sampled life-cycle stages {#sec019}
---------------------------------------------------------------

The putative HSP20 gene, which can express immunogenic products and stimulate the immune system, showed high expression in the oncosphere stage \[[@pntd.0004634.ref041], [@pntd.0004634.ref047]\]. The predicted HSP20 homologue (onco2) also showed the highest expression at the stages of non-activated oncosphere (RPKM = 6, 545.23) and also showed expression at the activated oncosphere stage and in early stage metacestodes as well ([Table 3](#pntd.0004634.t003){ref-type="table"}). Taken together with the findings from the published transcriptome of *E*. *multilocularis* \[[@pntd.0004634.ref023]\], it is clear that this molecule was expressed at almost all stages of *E*. *multilocularis*, including non-activated oncosphere, activated oncosphere, metacestode and adult worms.

The HSP70 family, which has been described as the major antigens in *Echinococcus* spp.\[[@pntd.0004634.ref048], [@pntd.0004634.ref049]\] and are the most striking gene family expansions with 22 full copies in *E*. *multilocularis* genomes version 3 \[[@pntd.0004634.ref023]\]. Furthermore, in various infectious disease models including echinococcosis, vaccination strategies using HSPs have produced significant protection \[[@pntd.0004634.ref048], [@pntd.0004634.ref050]\]. The transcriptome datasets of the present study show that HSP70 homologues were constantly expressed in all stages ([Table 3](#pntd.0004634.t003){ref-type="table"}). Continuous antigenic stimulation with parasite-derived HSP families would induce an apparent antibody response to these molecules in infected animals. These antibody responses create an opportunity to use HSPs in diagnostic assay and vaccine development for echinococcosis.

Antigen II/3 homologues constantly expressed in sampled life-cycle stages {#sec020}
-------------------------------------------------------------------------

Antigen II/3 share homology with the mammalian ezrin/radixin/moesin (ERM) protein family that is involved in several key processes related to cellular architecture, including cell-cell adhesion, membrane trafficking, microvillus formation and cell division \[[@pntd.0004634.ref051]\]. Antigen II/3 is encoded by the elp gene and the antigens of Em10 and Em18 are thought to be homologues, which have also been used as important diagnostic antigens \[[@pntd.0004634.ref052], [@pntd.0004634.ref053]\]. In the present study, antigen II/3 was highly expressed in all sequenced samples, but it had a relative higher expression level in non-activated and activated oncospheres. Previous studies proved that antigen II/3 can be expressed at the stages of protoscoleces, metecestode and adult and are localized within the germinal layer and parenchymal cell of protoscoleces and on the surface of calcareous corpuscles \[[@pntd.0004634.ref052]\]. Even though expression is relatively low in Cmet, there was no significant difference compared with the other collected data ([Table 3](#pntd.0004634.t003){ref-type="table"}). It has been shown that antigen II/3 is also constantly expressed in the early stage metacestodes and adults (FPKM\>200 \[[@pntd.0004634.ref023]\]).

The viability of protoscoleces was significantly reduced at day 10 after silencing the elp gene statistically \[[@pntd.0004634.ref054]\]. Together with the constantly high expression level of antigen II/3 at almost all life-cycle stages may hint that antigen II/3 has a fundamental role for supporting parasites, such that antigen II/3 can act not only as an important diagnostic antigen special for the oncosphere stage, but also as a vaccine candidate.

AgB subunit expression in non-activated and activated oncospheres {#sec021}
-----------------------------------------------------------------

Antigen B (AgB) was initially identified as major hydatid cyst fluid antigen of *E*. *granulosus* \[[@pntd.0004634.ref055]\]. In *E*. *multilocularis* genome version 3, there are seven isoforms that code antigen B subunits, of which EmAgB8/3 (EmuJ_000381500) had the highest expression (RPKM = 21, 686.21) among known antigens ([Table 3](#pntd.0004634.t003){ref-type="table"}) and was third highest expression of transcriptome of Cmet ([S2 Table](#pntd.0004634.s003){ref-type="supplementary-material"}); even activated oncospheres showed relative high expression (RPKM = 164.90). In addition, the three isoforms that code EmAgB3 were expressed not only in the early stage metacestode but also in the adult \[[@pntd.0004634.ref023]\] and non-activated and activated oncospheres ([Table 3](#pntd.0004634.t003){ref-type="table"}). Unlike other AgB subunits, which were almost within the 2-fold expression level of 4Wmet and Cmet, EmAgB2 showed a more than 10-fold difference. Previous studies have shown that the sensitivity of EgAgB2 was obviously different in different assays \[[@pntd.0004634.ref014], [@pntd.0004634.ref056]\], and one reason may be that *E*. *granulosus* isolated from CE patients in different countries expresses differing levels of the AgB2 subunit \[[@pntd.0004634.ref056]\]. Our data suggest this might be caused by differing expression of AgB2 within the early stage metacestodes. Furthermore, antibody responses to AgB in different cyst stages of different sensitivities \[[@pntd.0004634.ref004]\] also indicate that AgB subunits dynamically change in cyst stages. In conclusion, from the perspective of expression level, we proposed that EmAgB8/3 may be expected to have essential metabolic functions throughout all life-cycle stages of the parasite, while EmAgB8/1, EmAgB8/2, and EmAgB8/4 may be essential factors for survival of larvae in intermediate hosts. EmAgB8/5, which was firstly detected to be highly expressed in the adult of *E*. *multilocularis* \[[@pntd.0004634.ref057]\], but was not detected in this study.

Some Em-TSPs homologues with stages-specific expression {#sec022}
-------------------------------------------------------

Tetraspanins (TSPs) are a superfamily of plasma membrane-associated proteins consisting of four conserved transmembranes \[[@pntd.0004634.ref058]\]. They have been used as vaccine candidates against schistosomiasis, echinococcosis and as diagnostic antigens for cysticercosis \[[@pntd.0004634.ref002], [@pntd.0004634.ref020], [@pntd.0004634.ref059], [@pntd.0004634.ref060]\]; In addition, it was proven that tetraspanins in the tegument of schistosomula and adult worms can act as receptors for host ligands, including MHC molecules, allowing parasites to mask their non-self-status and escape host immune responses \[[@pntd.0004634.ref061]\]. A total of 11 amino acid sequences ([Table 3](#pntd.0004634.t003){ref-type="table"}) showed 91%-100% identity to the seven published Em-TSPs \[[@pntd.0004634.ref020]\]. In addition, there were two putative Em-TSP3 isoforms and two amino acid sequences of one isoform and three amino sequences of another isoform ([Table 3](#pntd.0004634.t003){ref-type="table"}), and most mutation sites were located at the LEL variable region ([Fig 6](#pntd.0004634.g006){ref-type="fig"}).

![Protein alignment of putative Em-TSP3 isoforms with four transmembrane.\
Fully conserved residues are marked with (\*), those replaced with amino acids of strongly similar properties with (:) and of weakly similar properties with (.) LEL variable region are in the solid line box and predicted transmembrane region are in the dashed line box. Protein mutant of the forth transmembrane is shaded in grey. There are three Em-TSP3 isoforms predicted, two of them are conserved with previous study \[[@pntd.0004634.ref023]\], but one of them are intermediate type of the former two isoforms and need further verification.](pntd.0004634.g006){#pntd.0004634.g006}

Previous transcriptome data \[[@pntd.0004634.ref023]\] and the present study showed that Em-TSP5 is expressed at almost all life-cycle stages and is significantly expressed at the stage of activated oncospheres and early stage metacestodes compared with non-activated oncosphere ([Table 3](#pntd.0004634.t003){ref-type="table"}). Em-TSP5 was intensely stained in sections of the germinal layer of metacestode \[[@pntd.0004634.ref020]\]. Em-TSP5 is closely related to the T24 antigen of *T*. *solium*, a diagnostic antigen for cysticercosis \[[@pntd.0004634.ref060]\], which suggest that Em-TSP5 may be an important diagnostic candidate for detecting early stage infection.

Em-TSP1, one of the highly protective vaccine candidates \[[@pntd.0004634.ref020]\], is located at the surface (germinal layer/tegument) of *E*. *multilocularis* larvae and the tegument of the adult worms. Significantly high expression in early stage metacestode compared with non-activated and activated oncospheres was observed ([Table 3](#pntd.0004634.t003){ref-type="table"}). A previous study showed that another protective effect vaccine candidate, Em-TSP3, is localized in the non-activated oncospheres and protoscoleces and the germinal layer of *E*. *multilocularis* cysts \[[@pntd.0004634.ref002]\]; the genome-mapped data in the present study showed relative higher expression in Aonc and 4Wmet than in Cmet (no protoscoleces), and the expression level of Em-TSP3 varied within non-activated oncospheres samples ([Table 3](#pntd.0004634.t003){ref-type="table"}). However, the *de novo* assembled data ([S4 Table](#pntd.0004634.s005){ref-type="supplementary-material"}) showed that Em-TSP3 homologues were highly expressed in both samples of non-activated oncospheres. In addition, the RPKM data in the present study could not distinguish the expression difference between two putative Em-TSP3 isoforms located in the same scaffold (pathogen_EMU_scaffold_007780, EmuJ_001077300 (pEm-TSP3-1), EmuJ_001077400 (pEm-TSP3-2)) ([Table 3](#pntd.0004634.t003){ref-type="table"}) of the parasite genome, and the visualization mapped reads showed that almost all reads from different samples can be simultaneously mapped to EmuJ_001077300 and EmuJ_001077400 genes, but there was an obvious SNP (G/A) of the mapped reads at the mapped positions of 13002639 and 13008462 in the scaffold and also in the fourth transmembrane region of the putative amino acid sequences of EmuJ_001077300 and EmuJ_001077400 that cause threonine to change to isoleucine ([Fig 6](#pntd.0004634.g006){ref-type="fig"} and [S1 Fig](#pntd.0004634.s001){ref-type="supplementary-material"}). Namely, 97% (8911, 8669G and 217,183A), 90% (1428, 1398G and 147, 146A), 78% (7,7G and 2, 2A) and 34% (11,11G and 21, 21A) of mapped reads were guanine of Nonc1, Aonc, 4Wmet and Cmet, respectively. The sequences from the *de novo* assembled data that showed 100% identity to EmuJ_001077300 were highly expressed and those with 100% identity to EmuJ_001077400 had relatively lower expression for Nonc and Aonc ([S4 Table](#pntd.0004634.s005){ref-type="supplementary-material"}). Furthermore, no transcripts showed 100% identity to EmuJ_001077300 in Cmet, and the expression level that showed 100% identity to EmuJ_001077400 was similar to oncosphere ([S4 Table](#pntd.0004634.s005){ref-type="supplementary-material"}). Together with mapped data and *de novo* assembled data, it is considerable that EmuJ_001077400 may be constantly expressed in oncospheres and metacestodes at a normal level and EmuJ_001077300 may show specific high expression in the oncospheres. The relatively higher ratio of guanine at polymorphic site in 4Wmet was also found to be different from that in Cmet but similar to those in oncospheres. Interestingly, the *de novo* assembled data identified an intermediate type isoform of pEm-TSP3 at the oncosphere stage ([Fig 6](#pntd.0004634.g006){ref-type="fig"}), which needs further verification.

Growing evidence suggests the importance of Th1/Th2 balance during parasite infections. Previous studies has shown that rEm-TSP3 may cause Th1 and Th2 responses by different immunization routes with Th2 being predominant \[[@pntd.0004634.ref002]\]. A recent study \[[@pntd.0004634.ref062]\] showed that rEg-TSP1 (95% identity to Em-TSP1) may cause a Th1 response. The stage-specific expression of Em-TSPs, especially Em-TSP1 and Em-TSP3, which are two of the most effective vaccines against echinococcosis, showed almost opposite expression at the same stage, suggesting that the two Em-TSPs may influence each other. Together with the 'tetraspanin web', which can lead to the dynamic assembly of tetraspanin family proteins dependent on the ability of its members to form lateral associations with multiple partner proteins and with each other \[[@pntd.0004634.ref063]\]. We propose that Em-TSP1 and Em-TSP2 can down-regulate each other. Further confirmation of the mutual inhibition of these two Em-TSPs may require a challenge experiment conducted *in vivo* or *in vitro*. The fact that some tetraspanin proteins cross-react with several others implies that immunization with one tetraspanin antigen could block several tetraspanins functions \[[@pntd.0004634.ref020]\] and the highly expressed of pEm-TSP3-1 in oncospheres hint that it could act as a specific vaccine in the early phase of infection.

Conclusion {#sec023}
----------

In this study, we have conducted RNA-Seq analysis of the oncospheres and early stage metacestodes of *E*. *multilocularis* (Nemuro strain). A global view of gene expression profiles and the stage-specific significant different express genes are revealed during the early invasion phases of the parasite. Further analysis show that tapeworm-specific AgB antigen family dominated in early stage metacestodes, GP50 antigen family dominated in activated oncospheres and Eg95 antigen are dominated in non-activated and activated oncospheres. In addition, heat shock proteins and antigen II/3 which contain highly conserved domain in invertebrates and vertebrates are constantly expressed in the three stages. The reveal of various known antigens expression level during the parasite development stages, especially the stages of non-activated and activated oncospheres, will give fundamental information for choosing candidate genes used in early diagnosis.

Supporting Information {#sec024}
======================

###### IGV view of putative Em-TSP3 isoforms in pathogen_EMU_scaffold_007780 of *E*. *multilocularis* genome versions 3.

The five tracks show the mapped result of EmuJ_001077300 (gene start: 13002559, gene end: 13003475) and EmuJ_001077400 (gene start: 13008382, gene end: 13009298) which all most reads can mapped to the two putative Em-TSP3 isoforms. At the locus of 13002639 and 13008462, there was two common single-nucleotide polymorphisms (SNPs) but the ratio of the two SNPs were obviously different among the samples.
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###### Significant different expressed genes in Non-activated oncospheres, Activted oncospheres and early stage of Metacestodes from Echinococcus multilocularis (P\<0.01, FDR\<0.05).
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###### Transcript data of dignostic antigen gp50 family in any of the sampled life cycle stage in this study and previous report \[[@pntd.0004634.ref023]\].
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###### BLASTX results of putative Em-TSP3 isoforms from different samples.
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